These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 26007666)

  • 1. Effects of CAP-regimen Chemotherapy on Blood Redox Status in Patients with Ovarian Cancer.
    Antoneeva II; Dolgova DR; Gening TP; Abakumova TV; Gening SO; Pirmamedova SS; Fomina AV; Mikheenko AA
    Anticancer Agents Med Chem; 2015; 15(9):1141-7. PubMed ID: 26007666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Redox-dependent processes in blood plasma, neutrophils and erythrocytes of patients with ovary cancer after polychemotherapy by CAP scheme].
    Gening TP; Abakumova TV; Dolgova DR; Antoneeva II; Gening SO; Pirmamedova SS; Fomina AV; Vasil'eva EV
    Antibiot Khimioter; 2014; 59(5-6):20-5. PubMed ID: 25552040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of CAR-regimen autohemochemotherapy on redox-dependent processes in erythrocytes of tumor-bearing organism in experimental ovarian cancer.
    Gening TP; Dolgova DR; Abakumova TV; Antoneeva II; Nasyrova EY; Gening SO
    Patol Fiziol Eksp Ter; 2016; 60(4):86-92. PubMed ID: 29244928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical efficacy analysis of chemotherapy to lymph node metastasis in epithelial ovarian cancer].
    Wu LY; Zhang R; Huang MN; Li N; Wang GX; Liu LY
    Ai Zheng; 2003 Apr; 22(4):424-7. PubMed ID: 12704005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The characteristics of redox-status of peripheral part of erythron under various localizations of neoplasm of organs of female reproductive sphere.].
    Gening TP; Fedotova AI; Dolgova DR; Abakumova TV; Antoneeva II
    Klin Lab Diagn; 2017; 62(8):468-472. PubMed ID: 30802392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of hexamethylmelamine in the combination chemotherapy of advanced ovarian cancer: a comparison of hexamethylmelamine, cyclophosphamide, doxorubicin, and cisplatin (H-CAP) versus cyclophosphamide, doxorubicin, and cisplatin (CAP).
    Hainsworth JD; Jones HW; Burnett LS; Johnson DH; Greco FA
    Am J Clin Oncol; 1990 Oct; 13(5):410-5. PubMed ID: 2121019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic overview of chemotherapy effects in ovarian cancer.
    Högberg T; Glimelius B; Nygren P;
    Acta Oncol; 2001; 40(2-3):340-60. PubMed ID: 11441940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients.
    Holloway RW; Mehta RS; Finkler NJ; Li KT; McLaren CE; Parker RJ; Fruehauf JP
    Gynecol Oncol; 2002 Oct; 87(1):8-16. PubMed ID: 12468336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy for stage III-IV ovarian cancer: the CAP-regimen in previously untreated patients.
    Meerpohl HG; Pfleiderer A; Kleine W; Teufel G
    Onkologie; 1982 Oct; 5(5):238-41. PubMed ID: 6760025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized trial of cisplatin, vinblastine, and bleomycin versus cyclophosphamide, aclacinomycin, and cisplatin in epithelial ovarian cancer.
    Tokuhashi Y; Kikkawa F; Tamakoshi K; Suganuma N; Kuzuya K; Arii Y; Kawai M; Hattori S; Kobayashi I; Furuhashi Y; Nakashima N; Tomoda Y
    Oncology; 1997; 54(4):281-6. PubMed ID: 9216851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of therapy on the antioxidant status in patients with melanoma.
    Gadjeva V; Dimov A; Georgieva N
    J Clin Pharm Ther; 2008 Apr; 33(2):179-85. PubMed ID: 18315784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy (CAP) for the treatment of advanced ovarian cancer and second-effort surgery in the second look.
    Ojeda-González MB; Alvárez-López I; Alonso-Muñoz MC; Badía-Serra J; Delgado-Latre E; de Andrés-Basauri L; López-López JJ
    Oncology; 1991; 48(1):7-12. PubMed ID: 1987501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomised comparison of cisplatin with cyclophosphamide/cisplatin and with cyclophosphamide/doxorubicin/cisplatin in advanced ovarian cancer. Gruppo Interegionale Cooperativo Oncologico Ginecologia.
    Lancet; 1987 Aug; 2(8555):353-9. PubMed ID: 2886821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens.
    Cantù MG; Buda A; Parma G; Rossi R; Floriani I; Bonazzi C; Dell'Anna T; Torri V; Colombo N
    J Clin Oncol; 2002 Mar; 20(5):1232-7. PubMed ID: 11870165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomised trial comparing combinations of cyclophosphamide and cisplatin without or with doxorubicin or 4'-epi-doxorubicin in the treatment of advanced ovarian cancer.
    Hernádi Z; Juhász B; Póka R; Lampé LG
    Int J Gynaecol Obstet; 1988 Oct; 27(2):199-204. PubMed ID: 2903085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial.
    International Collaborative Ovarian Neoplasm Group
    Lancet; 2002 Aug; 360(9332):505-15. PubMed ID: 12241653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of hexamethylmelamine (altretamine), cyclophosphamide, doxorubicin, and cisplatin (H-CAP) vs. cyclophosphamide, doxorubicin, and cisplatin (CAP) in advanced ovarian cancer.
    Greco FA; Johnson DH; Hainsworth JD
    Cancer Treat Rev; 1991 Mar; 18 Suppl A():47-55. PubMed ID: 1904309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
    Wadler S; Yeap B; Vogl S; Carbone P
    Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glutathione peroxidase, glutathione-S-transferase, catalase, xanthine oxidase, Cu-Zn superoxide dismutase activities, total glutathione, nitric oxide, and malondialdehyde levels in erythrocytes of patients with small cell and non-small cell lung cancer.
    Kaynar H; Meral M; Turhan H; Keles M; Celik G; Akcay F
    Cancer Lett; 2005 Sep; 227(2):133-9. PubMed ID: 16112416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glutathione, glutathione S-transferase alpha and pi, and aldehyde dehydrogenase content in relationship to drug resistance in ovarian cancer.
    Tanner B; Hengstler JG; Dietrich B; Henrich M; Steinberg P; Weikel W; Meinert R; Kaina B; Oesch F; Knapstein PG
    Gynecol Oncol; 1997 Apr; 65(1):54-62. PubMed ID: 9103391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.